Stock Performance: CANSINOBIO (06185.HK) experienced a decline of 1.840 points, or 4.614%, with short selling amounting to $25.56 million and a ratio of 15.536%.

Revenue Forecast: The company anticipates its revenue for the year ending December 31, 2025, to be between RMB1.04 billion and RMB1.08 billion.

Year-over-Year Growth: This projected revenue reflects an increase of RMB194 million to RMB234 million compared to the previous year, indicating a year-over-year growth of 22.88% to 27.61%.

Clinical Trial Initiation: CANSINOBIO has officially started a Phase I clinical trial for its DTcP-Hib-MCV4 Combined Vaccine, with the first patient enrolled.

Target Age Group: The trial aims to evaluate the safety and immunogenicity of the vaccine in children aged 2 months to 6 years.

UBS China Market Strategy Report: UBS has released a report highlighting Buy-rated Chinese stocks with significant potential for earnings growth by FY26, focusing on Hong Kong-listed and ADR-listed companies.

Highlighted Stocks: The report includes stocks such as INNOCARE, CARSGEN-B, ZAI LAB, AKESO, and CANSINOBIO, along with their recent performance and short selling data.

Short Selling Data: The report provides short selling figures for the listed stocks, indicating varying levels of short interest, with ZAI LAB and AKESO showing higher short selling ratios.

Related Market Insights: Additional context is provided by Soochow Securities, which lists the top 10 Hong Kong stocks with the highest net buys and sells by southbound funds in the previous week.

Stock Performance: CANSINOBIO (06185.HK) opened 2.2% higher at HKD48.46 and peaked at HKD51.8, closing at HKD51.3, an increase of 8.18%.

Short Selling Data: The company experienced short selling worth $3.94 million with a ratio of 3.914%.

Interim Results: The group reported interim revenue of RMB374 million, reflecting a year-on-year growth of 31.1%.

Loss Reduction: The company's loss significantly decreased from approximately RMB225 million to RMB13.485 million, marking a reduction of about 94%, with no dividend declared.